Literature DB >> 2187006

Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy.

E B Leite1, M C Mota, J R de Abreu, J G Cunha-Vaz.   

Abstract

The effect of calcium dobesilate on the alteration of the blood-retinal barrier was studied in 41 adult-onset, non-insulin dependent diabetic patients with minimal or no retinopathy, randomly assigned to receive either oral calcium dobesilate (1000 mg twice daily) or a placebo for 12 months. The posterior vitreous value and the penetration ratio, determined by vitreous fluorophotometry, reflected stabilisation of blood-retinal barrier permeability in the calcium dobesilate patients and deterioration of blood retinal barrier in those given placebo. During the relatively short period of the study, one year, no significant change in microaneurysm and capillary closure gradings was observed. No side effects were associated with calcium dobesilate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187006     DOI: 10.1007/bf00154206

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  16 in total

1.  The action of calcium dobesilate on capillary permeability in diabetics.

Authors:  R Sévin; J F Cuendet
Journal:  Ophthalmologica       Date:  1971       Impact factor: 3.250

2.  Inhibition of sorbitol formation in human erythrocytes by calcium dobesilate.

Authors:  M Schmidt; M Michal
Journal:  Arzneimittelforschung       Date:  1989-04

Review 3.  Platelet-activating factor--a powerful lipid autacoid possibly involved in microangiopathy.

Authors:  F Bussolino; P Biffignandi; P Arese
Journal:  Acta Haematol       Date:  1986       Impact factor: 2.195

4.  Early breakdown of the blood-retinal barrier in diabetes.

Authors:  J Cunha-Vaz; J R Faria de Abreu; A J Campos
Journal:  Br J Ophthalmol       Date:  1975-11       Impact factor: 4.638

5.  Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant human myometrium in vitro.

Authors:  G Falkay; L Kovács
Journal:  Experientia       Date:  1984-02-15

6.  Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy.

Authors:  I S Benarroch; M Brodsky; A Rubinstein; C Viggiano; E A Salama
Journal:  Ophthalmic Res       Date:  1985       Impact factor: 2.892

7.  Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy.

Authors: 
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-07       Impact factor: 4.799

8.  Quantification of diabetic macular edema.

Authors:  R T Smith; C M Lee; H C Charles; M Farber; J G Cunha-Vaz
Journal:  Arch Ophthalmol       Date:  1987-02

9.  Pathophysiology of diabetic retinopathy.

Authors:  J G Cunha-Vaz
Journal:  Br J Ophthalmol       Date:  1978-06       Impact factor: 4.638

10.  Characterization of the early stages of diabetic retinopathy by vitreous fluorophotometry.

Authors:  J G Cunha-Vaz; J R Gray; R C Zeimer; M C Mota; B M Ishimoto; E Leite
Journal:  Diabetes       Date:  1985-01       Impact factor: 9.461

View more
  12 in total

1.  Effect of qiming granule on retinal blood circulation of diabetic retinopathy: a multicenter clinical trial.

Authors:  Xiang-xia Luo; Jun-guo Duan; Pin-zheng Liao; Lie Wu; Yang-gui Yu; Bo Qiu; Yu-liang Wang; Yu-min Li; Zheng-qin Yin; Xiao-ling Liu; Ke Yao
Journal:  Chin J Integr Med       Date:  2009-10-03       Impact factor: 1.978

Review 2.  Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms.

Authors:  C Hernández; A Simó-Servat; P Bogdanov; R Simó
Journal:  J Endocrinol Invest       Date:  2017-03-29       Impact factor: 4.256

3.  Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study.

Authors:  Maria L Ribeiro; Andras I Seres; Angela M Carneiro; Michael Stur; Alain Zourdani; Patricia Caillon; José G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

4.  Effect of calcium dobesilate on retrobulbar blood flow and choroidal thickness in patients with non-proliferative diabetic retinopathy.

Authors:  Hossein Ashraf; Mehrzad Lotfi; Maryam Akbari; Hamidreza Jahanbani-Ardakani; Morteza Ghaffari; Mohammad Reza Khalili
Journal:  Int Ophthalmol       Date:  2021-08-02       Impact factor: 2.031

5.  Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes.

Authors:  Ermelindo C Leal; João Martins; Paula Voabil; Joana Liberal; Carlo Chiavaroli; Jacques Bauer; José Cunha-Vaz; António F Ambrósio
Journal:  Diabetes       Date:  2010-07-13       Impact factor: 9.461

Review 6.  Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review.

Authors:  Rafael Simó; Stefania Ballarini; José Cunha-Vaz; Linong Ji; Hermann Haller; Paul Zimmet; Tien Y Wong
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

7.  Mechanisms of retinal neuroprotection of calcium dobesilate: therapeutic implications.

Authors:  Olga Simó-Servat; Cristina Solà-Adell; Patricia Bogdanov; Cristina Hernández; Rafael Simó
Journal:  Neural Regen Res       Date:  2017-10       Impact factor: 5.135

Review 8.  Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy.

Authors:  Toshiyuki Oshitari
Journal:  Int J Environ Res Public Health       Date:  2021-12-31       Impact factor: 3.390

9.  Calcium dobesilate alleviates renal dysfunction and inflammation by targeting nuclear factor kappa B (NF-κB) signaling in sepsis-associated acute kidney injury.

Authors:  Zhijuan Xie; Lanji Wei; Jianying Chen; Zhong Chen
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

Review 10.  Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids.

Authors:  Hervé Allain; Albert A Ramelet; Elisabeth Polard; Danièle Bentué-Ferrer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.